Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Verbio Vereinigte Bioenergie Ag

Lead Discovery Center Gmbh

Jan Kühling

Michael I Bukrinsky

Michael Schlimbach

Oliver Lüdtke

Gunter Fischer

Stephanie Constant

Frank Erdmann

Gerd Ruhter

Peter Nussbaumer

Gerd Rühter

Miroslav Malesevic

Anne Lamp

Wolfram Klein

Julia Pohl

Enrico Fichter

Klaus Dinkel

Georg Pollert

Jens Horn

1) A method for obtaining a concentrated protein-rich phase from residues of bioethanol production. 2.1) Previously, the separation of a protein-rich phase from whole stillage from bioethanol production has been achieved either by the addition of chemicals or by process steps that are complex in terms of equipment and/or energy. 2.2) Whole stillage from bioethanol production is fed to a solid-liquid separation, and the liquid phase (thin stillage) resulting from this is partially returned to the mashing process. This recirculation increases the raw protein content in the process. Part of the thin stillage is diluted and fed to a simple separation process without the addition of chemicals and temperature treatment, with a protein-rich phase being obtained. 2.3) A protein-rich phase is obtained from residues of bioethanol production.

Process for obtaining a concentrated protein-rich phase from waste products of bioethanol production

The invention relates to a method for producing biogas from lignocellulose-containing biomass, preferably from straw, and to a plant for carrying out said method.

Method and plant for producing biogas from lignocellulose-containing biomass

The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.

Cyclosporin derivatives

A cyclosporin derivative of general Formula (I) or a pharmaceutically compatible salt thereof, which have a pharmaceutical effectiveness, for example in the case of chronic inflammatory diseases. The cyclosporin derivatives are preferably free from a peptide section capable of passing through the membrane of a biological cell.

Growing community of inventors

Halle, Germany

Jan Kühling